All In Biotech

Drug Trial Radar · NCT03816176

A Study to Evaluate Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Participants

A Phase 2, Open-Label, Non-Comparative, Multicenter Study to Evaluate the Safety and Tolerability, Efficacy and Pharmacokinetics of Isavuconazonium Sulfate for the Treatment of Invasive Aspergillosis (IA) or Invasive Mucormycosis (IM) in Pediatric Subjects

Last checked: Nov 20, 2026Latest source record: Dec 5, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

31

Actual

Start

Aug 22, 2019

Primary completion

Dec 14, 2022

Study completion Dec 14, 2022

Sponsor

Lead sponsor
Astellas Pharma Global Development, Inc.Astellas (ALPMY)
Sponsor type
Industry
First posted
Jan 25, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 1 year, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to evaluate the safety, tolerability, and efficacy of isavuconazonium sulfate in pediatric participants.

Conditions

  • Invasive Mucormycosis
  • Invasive Aspergillosis

Interventions

  • Isavuconazonium sulfateDrug

    Intravenous (IV) infusion

  • Isavuconazonium sulfateDrug

    Oral capsule

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs)Time frame: From first dose to 30 days after the last dose (maximum 210 Days)
  2. Percentage of Participants With All - Cause Mortality Through Day 42Time frame: Baseline up to 42 days

Locations

10 sites in 3 countries. Site status is shown where the registry gives one.

  • Children's Hospital, Los Angeles

    Los Angeles, California

  • University of California - Los Angeles

    Los Angeles, California

  • Children's Hospital of Orange County

    Orange, California

  • Children's National Medical Center

    Washington D.C., District of Columbia

  • Ann & Robert H. Lurie Children's Hospital of Chicago

    Chicago, Illinois

  • Site BE32001

    Ghent, Belgium

  • Site BE32002

    Leuven, Belgium

  • Site ES34002

    Barcelona, Spain

  • Site ES34003

    Madrid, Spain

  • Site ES34001

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.